Publications
Detailed Information
High-resolution snapshots of proteasome inhibitors in action revise inhibition paradigms and inspire next-generation inhibitor design
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Carmony, Kimberly | - |
dc.contributor.author | Lee, Wooin | - |
dc.contributor.author | Kim, Kyung Bo | - |
dc.date.accessioned | 2017-04-25T07:47:00Z | - |
dc.date.available | 2017-07-26T15:01:20Z | - |
dc.date.created | 2017-11-15 | - |
dc.date.issued | 2016-11 | - |
dc.identifier.citation | ChemBioChem, Vol.17 No.22, pp.2115-2117 | - |
dc.identifier.issn | 1439-4227 | - |
dc.identifier.uri | https://hdl.handle.net/10371/117528 | - |
dc.description.abstract | The proteasome, which mediates the ubiquitin-dependent degradation of intracellular proteins, is well recognized as an important anticancer target (Figure 1). So far, three inhibitors of this multiprotease complex have received FDA approval for treating multiple myeloma: the peptide boronic acids bortezomib and ixazomib and the peptide epoxyketone carfilzomib.([1]) Several other proteasome inhibitors have entered clinical trials, including the peptide boronic acid delanzomib and the peptide epoxyketone oprozomib.([2]) [GRAPHICS] . | - |
dc.language | 영어 | - |
dc.language.iso | en | en |
dc.publisher | John Wiley & Sons Ltd. | - |
dc.title | High-resolution snapshots of proteasome inhibitors in action revise inhibition paradigms and inspire next-generation inhibitor design | - |
dc.type | Article | - |
dc.contributor.AlternativeAuthor | 이우인 | - |
dc.contributor.AlternativeAuthor | 김경보 | - |
dc.identifier.doi | 10.1002/cbic.201600488 | - |
dc.citation.journaltitle | ChemBioChem | - |
dc.identifier.wosid | 000392929400002 | - |
dc.identifier.scopusid | 2-s2.0-84991094051 | - |
dc.description.srnd | OAIID:RECH_ACHV_DSTSH_NO:T201616321 | - |
dc.description.srnd | RECH_ACHV_FG:RR00200001 | - |
dc.description.srnd | ADJUST_YN: | - |
dc.description.srnd | EMP_ID:A079739 | - |
dc.description.srnd | CITE_RATE:2.85 | - |
dc.description.srnd | FILENAME:Carmony_et_al-2016-ChemBioChem.pdf | - |
dc.description.srnd | DEPT_NM:제약학과 | - |
dc.description.srnd | EMAIL:wooin.lee@snu.ac.kr | - |
dc.description.srnd | SCOPUS_YN:Y | - |
dc.description.srnd | FILEURL:https://srnd.snu.ac.kr/eXrepEIR/fws/file/cc8c4840-372e-45ca-b9e3-85b0151a0515/link | - |
dc.description.srnd | CONFIRM:Y | - |
dc.citation.endpage | 2117 | - |
dc.citation.number | 22 | - |
dc.citation.startpage | 2115 | - |
dc.citation.volume | 17 | - |
dc.description.isOpenAccess | Y | - |
dc.contributor.affiliatedAuthor | Lee, Wooin | - |
dc.identifier.srnd | T201616321 | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.subject.keywordPlus | 20S PROTEASOME | - |
dc.subject.keywordPlus | CRYSTAL-STRUCTURE | - |
dc.subject.keywordPlus | MULTIPLE-MYELOMA | - |
dc.subject.keywordPlus | ANGSTROM RESOLUTION | - |
dc.subject.keywordPlus | CARFILZOMIB | - |
dc.subject.keywordPlus | MECHANISM | - |
dc.subject.keywordPlus | COMPLEX | - |
dc.subject.keywordPlus | YEAST | - |
dc.subject.keywordAuthor | drug design | - |
dc.subject.keywordAuthor | epoxyketone | - |
dc.subject.keywordAuthor | oprozomib | - |
dc.subject.keywordAuthor | proteasome inhibitors | - |
dc.subject.keywordAuthor | proteasome structures | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.